Acutus Medical, Inc. (AFIB) Tops Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Acutus Medical Reports First Quarter 2023 Financial Results
May 11, 2023 4:01 PM EDTCARLSBAD, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (Acutus or the Company) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2023.
Recent Highlights:
Reported revenue of $4.2 million for the first quarter of 2023, a 13% increase compared to $3.7 million for the same quarter last year.Continued improvement in financial performance with year-over-year reductions of 58% in GAAP operating expenses, and year-over-year reductions of 39% in both non-GAAP... More